

CURRICULUM VITAE



PERSONAL INFORMATION

Name **CLAUDIA CECI**
Home address [REDACTED] **Veroli (FR), Italy**
Phone number [REDACTED]
E-mail address **claudiaceci@hotmail.it**
Nationality Italian
Date and place of birth 05/07/1985, VEROLI (FR)
Tax code CCECLD85L45L780D

RESEARCH EXPERIENCE

Dates **FEBRUARY 2018 – TO DATE**
Name of employer University of Rome Tor Vergata
Type of business or sector Medical School, Department of Systems Medicine, laboratory of Pharmacology
Occupation or position held Research collaboration with Biostilogit Pharmaceuticals Srl, Via Lilliano e Meoli, 78, 50012 Bagno a Ripoli (FI)
Main activities and responsibilities
- Direct participation in every phase of the research project entitled "Antitumor activity of ellagic acid encapsulated in biocompatible polymers microspheres"
- Direct participation in every phase of the research project supported by the Italian Association for Cancer Research entitled "Validation and humanization of a novel anti-VEGFR-1 monoclonal antibody for malignant melanoma treatment" (AIRC, Investigator Grant IG 2017 N. 203553)

Dates **DECEMBER 2014 – JULY 2016**
Name of employer University of Rome Tor Vergata
Type of business or sector Medical School, Department of Systems Medicine, laboratory of Pharmacology
Occupation or position held Post-doctoral fellow
Main activities and responsibilities
- Direct participation in every phase of the research project entitled "Apoptotic and anti-proliferative activity of ellagic acid against bladder cancer cell models", in collaboration with Biostilogit Pharmaceuticals Srl, Via Lilliano e Meoli, 78, 50012 Bagno a Ripoli (FI)
- Direct participation in every phase of the research project supported by the Italian Association for Cancer Research entitled "Targeting of VEGFR-1 and PARP-1 to reduce chemoresistance of glioblastoma and glioblastoma stem cells" (AIRC, Investigator Grant IG 2013 N. 14042)

Dates	DECEMBER 2011 – NOVEMBER 2014
Name of employer	University of Rome Tor Vergata
Type of business or sector	Medical School, Department of Systems Medicine, laboratory of Pharmacology
Occupation or position held	PhD student in Neuroscience
Main activities and responsibilities	Direct participation in every phase of the research project, from programming to laboratory activities [Aim of the study: nickel exposure effect on neuronal differentiation]
Dates	NOVEMBER 2010 - APRIL 2011
Name of employer	University of Rome Tor Vergata
Type of business or sector	Medical School, Department of Neuroscience, laboratory of Pharmacology
Occupation or position held	Pre-doctoral fellow
Main activities and responsibilities	Direct participation in every phase of the research project and laboratory activities [Aim of the study: caspases role in neuronal differentiation]
Dates	NOVEMBER 2008 - MAY 2010
Name of employer	University of Rome Tor Vergata
Type of business or sector	Department of Biology, laboratory of Cell and Developmental Biology
Occupation or position held	Graduating student for the degree (II level) in Cell and Molecular Biology
Main activities and responsibilities	Direct participation in every phase of the experimental thesis project and laboratory activities

Dates	MARCH 2007 - JUNE 2007
Name of employer	University of Rome Tor Vergata
Type of business or sector	Department of Biology, laboratory of Biochemistry
Occupation or position held	Graduating student for the degree (I level) in Cell and Molecular Biology
Main activities and responsibilities	Participation in laboratory activities

EDUCATION AND TRAINING

Dates	DECEMBER 2011 - MAY 2014
Name and type of organisation providing education and training	University of Rome Tor Vergata; Faculty of Medicine
Main subjects / professional abilities	Neurosciences, Developmental and cell biology
Title of qualification awarded	PhD in Neurosciences, Thesis title: "Effect of nickel exposure on neuronal differentiation"
Dates	OCTOBER 2007 - MAY 2010
Name and type of organisation providing education and training	University of Rome Tor Vergata; Faculty of Mathematical, Physical and Natural Sciences
Main subjects / professional abilities	Developmental and cell biology, biochemistry, genetic, molecular biology

Title of qualification awarded	Degree in Cellular and Molecular Biology, 110/110 <i>cum laude</i>
Level in national classification	Second level specialistic degree Thesis title: "Reticulon 1-C effect in chemotherapeutic treatment of human mammal adenocarcinoma MCF-7 cells"
Dates	OCTOBER 2004 - OCTOBER 2007
Name and type of organisation providing education and training	University of Rome Tor Vergata; Faculty of Mathematical, Physical and Natural Sciences
Main subjects / professional abilities	Genetic, biochemistry, cell biology, molecular biology
Title of qualification awarded	Degree in Cellular and Molecular Biology, 110/110 <i>cum laude</i>
Level in national classification	First level degree Thesis title: "Human DNA Topoisomerase I: analysis of mutations that could make the enzyme resistant to the antitumor drug camptothecin"
Dates	SEPTEMBER 1999 - JUNE 2004
Name and type of organization providing education and training	Scientific High School "Giovanni Sulpicio" in Veroli (Frosinone, Italy), socio-psycho-pedagogical address
Title of qualification awarded	High School Diploma, 100/100

TEACHING EXPERIENCE

- Lecturer of lessons concerning chemotherapy, anticoagulants and anti-inflammatory drugs
- High school substitute teacher (Biology course, October - November 2018)
- Course of Special Pharmacology and Therapy, module I, Degree of Pharmacy, University of Rome "Tor Vergata" (English course, march 2019)

PERSONAL SKILLS AND COMPETENCES

MOTHER TONGUE **ITALIAN**

OTHER LANGUAGES

ENGLISH
 Reading GOOD
 Writing GOOD
 Oral expression GOOD

FRENCH
 Reading GOOD
 Writing SUFFICIENT
 Oral expression SUFFICIENT

**TECHNICAL SKILLS AND
COMPETENCES**

- EUKARYOTIC CELL CULTURES: PHARMACOLOGICAL TREATMENT WITH ANTITUMOR DRUGS AND VIABILITY ASSAYS
- BACTERIAL CULTURES AND TRANSFORMATION
- DNA AND PROTEIN EXTRACTION FROM CELLS
- WESTERN BLOT
- IMMUNOPRECIPITATION
- PCR
- ELISA
- TRANSFECTION WITH LIPOFECTAMINE
- INVASION AND MIGRATION ASSAYS
- HUMAN TUMOR XENOGRAFT MODELS FOR PRECLINICAL ASSESSMENT OF ANTICANCER DRUGS AND NUTRIENTS COMPONENTS

PUBLICATIONS

Garufi A, Pistrutto G, **Ceci C**, Di Renzo L, Santarelli R, Faggioni A, Cirone M, D'Orazi G. Targeting COX-2/PGE(2) pathway in HIPK2 knockdown cancer cells: impact on dendritic cell maturation. PLoS One. 2012;7(11)

Pistrutto G, Papaleo V, Sanchez P, **Ceci C**, Barbaccia ML. Divergent modulation of neuronal differentiation by Caspase-2 and -9. PLoS One. 2012;7(5)

Ceci C, Barbaccia ML, Pistrutto G. A not cytotoxic nickel concentration alters the expression of neuronal differentiation markers in NT2 cells. Neurotoxicology. 2015;47:47-53

Graziani G, Artuso S, De Luca A, Muzi A, Rotili D, Scimeca M, Atzori MG, **Ceci C**, Mai A, Leonetti C, Levati L, Bonanno E, Tentori L, Caccuri AM (2015). A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. Biochem Pharmacol. 95(1):16-27

Pistrutto G, Trisciuglio D, **Ceci C**, Garufi A, D'Orazi G. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY). 2016 (4):603-19. Review

Ceci C, Tentori L, Atzori MG, Lacal PM, Bonanno E, Scimeca M, Cicconi R, Mattei M, de Martino MG, Vespasiani G, Miano R, Graziani G (2016). Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth. Nutrients 8(11)

Atzori MG, Tentori L, Ruffini F, **Ceci C**, Lisi L, Bonanno E, Scimeca M, Eskilsson E, Daubon T, Miletic H, Ricci Vitiani L, Pallini R, Navarra P, Bjerkvig R, D'Atri S, Lacal PM, Graziani G. The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells. J Exp Clin Cancer Res. 2017; 36(1):106

Cacciotti I, **Ceci C**, Bianco A, Pistrutto G. Neuro-differentiated Ntera2 cancer stem cells encapsulated in alginate beads: First evidence of biological functionality. Mater Sci Eng C Mater Biol Appl. 2017;81:32-38

Atzori MG, Tentori L, Ruffini F, **Ceci C**, Bonanno E, Scimeca M, Lacal PM, Graziani G. The Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody D16F7 Inhibits Glioma Growth and Angiogenesis In Vivo. J Pharmacol Exp Ther. 2018; 364(1):77-86

Ceci C, Lacal PM, Tentori L, De Martino MG, Miano R, Graziani G. Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid. Nutrients. 2018; 10(11). Review

Rome, 10th March 2019

